U.S. UREA CYCLE DISORDERS TREATMENT MARKET ANALYSIS

U.S. Urea Cycle Disorders Treatment Market, By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)-

Published In : Mar 2023
Code : CMI5594
Pages :155
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

U.S. Urea Cycle Disorders Treatment Market: Key Developments

Increasing collaboration for urea cycle disorders treatment by market players is expected to propel the growth of the U.S. Urea Cycle Disorders Treatment market over the forecast period. For instance, in January 2021, Recordati Rare Diseases Inc., a biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for CARBAGLU for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) in pediatric. CARBAGLU was previously approved by U.S. Food Drug and Administration in the year 2021 for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency.

U.S. UREA CYCLE DISORDERS TREATMENT MARKET ANALYSIS

Market News

U.S. Urea Cycle Disorders Treatment Market Report Snapshots

EXISTING CLIENTELE